New Delhi, Sept. 17 -- Indian drugmakers queuing up to launch copies of blockbuster weight-loss drugs Ozempic and Wegovy next year might have a perception crisis on their hands. More than 1,800 court cases have been filed in the US by users claiming they were not warned about the severe side effects of these medications.

Ozempic and Wegovy's Danish drugmaker Novo Nordisk and Mounjaro's US-based Eli Lilly and Co. have denied the claims.

But as Sun Pharmaceutical Industries Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd and other Indian drugmakers prepare to launch cheaper versions of semaglutide, the compound behind Ozempic, Wegovy and Rybelsus, experts say the lawsuits will have little impact on domestic sales.

Semaglutide is set to lose ...